Guardant Health, Inc

General information
Guardant Health, Inc
505 Penobscot Dr.
94063 Redwood City, California

Contact person: Helmy Eltoukhy, Chief Executive Officer and Chairman
Company main phone: +1 (855) 6988887
Company main fax:  +1 (888) 9744258
Year founded:2012
Source of foundation:Independent foundation
No. of employees: Worldwide:  1793
Corporate description / mission:
Guardant Health is a precision oncology company focused on cancer diagnostics through use of the proprietary blood tests, vast data sets and advanced analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2018
  • Biotechnology - Therapeutics and Diagnostics
  • Molecular diagnostics
  • Other
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Manufacturer
  • R&D
  • Service company
  • Supplier / Distributor
Customer segments:
  • Consumers (mass market)
  • Hospitals
  • Large medtech
  • Physicians / doctors
  • Direct (own sales force)
Summary Products / Services / Technologies
Description of products:
Guardant360® CDx
Guardant Reveal™ test
LUNAR-2 test
Financing details
Fiscal year (end of) 2022
Revenues:USD 449.54M
R&D expenses:USD 373.81M
No. of shares:102'664'000
Market cap. / valuation:USD 2'664.13M
Collaborations & Clients
Partnering strategy / collaborations:
The company work with bio-pharmaceutical partners, digital health companies, patient advocacy groups and international distributors.